CLINICAL STUDY: SIGNIFICANCE OF ELECTROCARDIOGRAPHIC ABNORMALITIES
Microalbuminuria modifies the mortality risk associated with electrocardiographic ST-T segment changes
Gilles F. H. Diercks, MD*,*,
Hans L. Hillege, MD*,
A. d J. van Boven, MD ,
Jan A. Kors, PhD ,
Harry J. G. M. Crijns, MD,
Diederick E. Grobbee, MD ,
Paul E. de Jong, MD|| and
Wiek H. van Gilst, PhD*
* Department of Clinical Pharmacology, University of Groningen, Groningen, The Netherlands
Department of Cardiology, Academic Hospital, Groningen, The Netherlands
Department of Medical Informatics, Erasmus University, Rotterdam, The Netherlands
Julius Center for Patient Oriented Research, University Medical Center, Utrecht, The Netherlands
|| Department of Nephrology, Academic Hospital, Groningen, The Netherlands
Manuscript received January 22, 2002;
revised manuscript received May 28, 2002,
accepted June 7, 2002.
* Reprint requests and correspondence: Dr. Gilles F. H. Diercks, Department of Clinical Pharmacology, University of Groningen, A. Deusinglaan 1, 9713 AV, Groningen, The Netherlands.
g.f.h.diercks{at}med.rug.nl
OBJECTIVES: We sought to investigate whether microalbuminuria, a proposed marker of generalized vascular damage, enhances the prognostic value of ST-T segment changes for all-cause and cardiovascular mortality in the general population.
BACKGROUND: ST-T segment changes on the rest electrocardiogram (ECG) predict mortality in the general population. However, the excess risk seems to be low, particularly in nonhospitalized populations with a low cardiovascular risk profile.
METHODS: In a population of 7,330 male and female subjects, a total of 89 deaths (1.2%) occurred during a median three-year follow-up. In 69 of these, the cause of death was obtained from the Central Bureau of Statistics: 25 subjects died of cardiovascular causes (36%). Using computerized Minnesota coding, ST-T segment changes were coded as 4.1-4 and 5.1-4. Microalbuminuria was defined as a urinary albumin excretion of 30 to 300 mg per 24 h.
RESULTS: The combination of ST-T segment changes and microalbuminuria showed a higher hazard ratio (HR) for all-cause mortality (HR 8.6 [95% confidence interval [CI] 4.8 to 15.2, p < 0.0001), as compared with ST-T segment changes in the absence of microalbuminuria (HR 1.3 [95% CI 0.7 to 2.5]), which was independent of other cardiovascular risk factors (HR 3.3 [95% CI 1.5 to 7.1], p = 0.002). The combination showed a higher HR when only cardiovascular deaths were taken into account, as compared with all-cause mortality (HR 24.5 [95% CI 7.9 to 76.0], p < 0.0001), which also counted for ST-T segment changes alone (HR 4.4 [95% CI 1.4 to 14.5], p = 0.02). After controlling for other risk factors, the HRs were 10.4 (95% CI 2.5 to 43.6, p = 0.001) for the combination and 2.7 (95% CI 0.6 to 12.3) for ST-T segment changes alone.
CONCLUSIONS: This study suggests that, in subjects with ST-T segment changes on their rest ECG, microalbuminuria could identify those at increased risk of all-cause and cardiovascular mortality.
|
Abbreviations and Acronyms
| | CI | | confidence interval | | ECG | | electrocardiogram | | HR | | hazard ratio | | PREVEND | | Prevention of REnal and Vascular ENd-stage Disease study |
|
This article has been cited by other articles:
|
|
|
|
 
S. Sheehan, S.-W. Tsaih, B. L. King, C. Stanton, G. A. Churchill, B. Paigen, and K. DiPetrillo
Genetic analysis of albuminuria in a cross between C57BL/6J and DBA/2J mice
Am J Physiol Renal Physiol,
November 1, 2007;
293(5):
F1649 - F1656.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Schmieder, C. Delles, A. Mimran, J. P. Fauvel, and L. M. Ruilope
Impact of Telmisartan Versus Ramipril on Renal Endothelial Function in Patients With Hypertension and Type 2 Diabetes
Diabetes Care,
June 1, 2007;
30(6):
1351 - 1356.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Weir
Microalbuminuria and Cardiovascular Disease
Clin. J. Am. Soc. Nephrol.,
May 1, 2007;
2(3):
581 - 590.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Morganti
Randomized Clinical Trials on Surrogate End Points: Are They Useful for Evaluating Cardiovascular and Renal Disease Protection in Hypertension? The Case for Yes
J. Am. Soc. Nephrol.,
April 1, 2006;
17(4_suppl_2):
S141 - S144.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Schmieder, A. U. Klingbeil, E. H. Fleischmann, R. Veelken, and C. Delles
Additional Antiproteinuric Effect of Ultrahigh Dose Candesartan: A Double-Blind, Randomized, Prospective Study
J. Am. Soc. Nephrol.,
October 1, 2005;
16(10):
3038 - 3045.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Okin, M. J. Roman, L. G. Best, E. T. Lee, J. M. Galloway, B. V. Howard, and R. B. Devereux
C-Reactive Protein and Electrocardiographic ST-Segment Depression Additively Predict Mortality: The Strong Heart Study
J. Am. Coll. Cardiol.,
June 7, 2005;
45(11):
1787 - 1793.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Korstanje and K. DiPetrillo
Unraveling the genetics of chronic kidney disease using animal models
Am J Physiol Renal Physiol,
September 1, 2004;
287(3):
F347 - F352.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Okin, M. J. Roman, E. T. Lee, J. M. Galloway, B. V. Howard, and R. B. Devereux
Combined Echocardiographic Left Ventricular Hypertrophy and Electrocardiographic ST Depression Improve Prediction of Mortality in American Indians: The Strong Heart Study
Hypertension,
April 1, 2004;
43(4):
769 - 774.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. K. Olijhoek, Y. van der Graaf, J.-D. Banga, A. Algra, T. J. Rabelink, F. L. J. Visseren, and for the SMART Study Group
The Metabolic Syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm
Eur. Heart J.,
February 2, 2004;
25(4):
342 - 348.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Sarnak, A. S. Levey, A. C. Schoolwerth, J. Coresh, B. Culleton, L. L. Hamm, P. A. McCullough, B. L. Kasiske, E. Kelepouris, M. J. Klag, et al.
Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention
Hypertension,
November 1, 2003;
42(5):
1050 - 1065.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Sarnak, A. S. Levey, A. C. Schoolwerth, J. Coresh, B. Culleton, L. L. Hamm, P. A. McCullough, B. L. Kasiske, E. Kelepouris, M. J. Klag, et al.
Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention
Circulation,
October 28, 2003;
108(17):
2154 - 2169.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.M. Sharma
Renal involvement in hypertensive cardiovascular disease
Eur. Heart J. Suppl.,
August 1, 2003;
5(suppl_F):
F12 - F18.
[Abstract]
[PDF]
|
|
|
|
